Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novo Nordisk |
---|---|
Information provided by: | Novo Nordisk |
ClinicalTrials.gov Identifier: | NCT00184730 |
This trial is conducted in Japan. This protocol describes an extension trial to supply hGH to subjects who wish continuous treatment after the long-term Phase 3 trial (GHLiquid-1519) until hGH products have been approved for GHDA in Japan.
Condition | Intervention | Phase |
---|---|---|
Growth Hormone Deficiency (GHD) |
Drug: somatropin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Investigation of the Efficacy and Safety of hGH in Long Term (More Than 48 Weeks) in GHDA. |
Estimated Enrollment: | 115 |
Study Start Date: | November 2004 |
Ages Eligible for Study: | 19 Years to 67 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Novo Nordisk A/S ( Public Access to Clinical Trials ) |
Study ID Numbers: | GHLIQUID-1650, JAPIC: JapicCTI-050134 |
Study First Received: | September 13, 2005 |
Last Updated: | November 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00184730 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Dwarfism Bone Diseases, Endocrine Hypopituitary dwarfism Hypothalamic Diseases Pituitary Diseases Endocrine System Diseases Central Nervous System Diseases Dwarfism, Pituitary |
Brain Diseases Bone Diseases Growth hormone deficiency Musculoskeletal Diseases Hypopituitarism Bone Diseases, Developmental Endocrinopathy |
Nervous System Diseases |